Golimumab rejected by NICE for psoriatic arthritis

Golimumab has not been recommended by NICE for use in treating psoriatic arthritis, under draft guidance issued by the institute.

The drug is licensed for the treatment of active and progressive arthritis in adults unresponsive to other therapy.

NICE has made the recommendation because research indicates that golimumab is not more cost-effective than other available options.

A spokesman said: 'NICE currently recommends adalimumab, etanercept and infliximab for the treatment of psoriatic arthritis in people who have peripheral arthritis. The cost-effectiveness analyses found that golimumab was not the most cost effective of the available options currently recommended by NICE.'

A secondary reason for the guidance was uncertainty about possible harmful side-effects of taking the drug, as a long-term follow up on adverse outcomes is ongoing.

The spokesman added: 'Based on the available evidence, golimumab was expected to be more costly than estimated in the economic model and less cost effective than etanercept, and so could not be considered a good use of NHS resources.'

The draft guidance is currently open to consultation.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

GPs report drop in older patients coming forward with cancer symptoms

GPs report drop in older patients coming forward with cancer symptoms

More than half of GPs say numbers of older patients coming forward with cancer symptoms...

Failure to involve GPs in COVID-19 test and trace 'a disaster and a national shame'

Failure to involve GPs in COVID-19 test and trace 'a disaster and a national shame'

GPs and primary care teams should have played a key role in the UK’s efforts to test,...

RCGP chair 'livid' over attacks on general practice from 'armchair critics'

RCGP chair 'livid' over attacks on general practice from 'armchair critics'

General practice has risen 'heroically' to unprecedented challenges during the COVID-19...

Remote GP consultations a 'lifeline for the NHS' during pandemic, says Hancock

Remote GP consultations a 'lifeline for the NHS' during pandemic, says Hancock

The rapid switch to remote GP consultations during the COVID-19 pandemic provided...

COVID-19 disrupted training for four in five doctors, GMC survey shows

COVID-19 disrupted training for four in five doctors, GMC survey shows

The vast majority of trainee doctors have seen their training disrupted or limited...

GP practices face losses 'in excess of £50,000' as COVID-19 hits income

GP practices face losses 'in excess of £50,000' as COVID-19 hits income

GP practices across England are facing a significant loss of income as COVID-19 dries...